US-China TechBio startup Aureka Biotechnologies has closed a $100 million Series B to build what it calls a "biological world model" for drug discovery. The round, announced August 10, 2026, was funded first exclusively by Granite Asia, with a subsequent tranche led by an unnamed strategic investor and joined by HighLight Capital, MPCi and NRL Capital. Aureka has now raised nearly $200 million to date.
A biological foundation model
Founded in 2023, Aureka is one of a small handful of companies trying to do for biology what frontier labs have done for language — build a general-purpose foundation model that understands, generates, predicts and intervenes in biological systems. The company pairs its models with a proprietary Lab-in-the-Loop platform: automated single-cell functional screening and high-throughput experimentation designed to feed real-world data back into training.
Where the money goes
Aureka says the Series B will primarily fund research and large-scale training of its next generation of biological foundation models, with a focus on de novo molecular design, biological structure modeling and function prediction. A meaningful slice will also upgrade its automation stack and the closed-loop link between models and physical experiments.
TechBio's mega-round moment
The round arrives as investors continue to write outsized checks against the thesis that AI foundation models unlock a step-change in drug discovery. It follows a summer of billion-dollar AI infrastructure rounds — from River AI's $1.1B raise to Nvidia's $500B financing platforms — and mirrors recent surgical-AI momentum such as the J&J OTTAVA FDA authorization.
Positioning against the incumbents
Aureka is entering a market already crowded with well-funded AI-drug-discovery peers, but its explicit framing of a general "biological world model" pushes it into direct comparison with efforts at Isomorphic Labs, Recursion and Xaira. If its Lab-in-the-Loop platform can compound learning across programs, the company argues, it can shift the economics of preclinical R&D at a portfolio level rather than one asset at a time.
Reporting based on coverage from BioSpace, PR Newswire and Aureka Biotechnologies.